Skip to main content
Natsuo Tomita on Muck Rack

Natsuo Tomita

As seen in: Nature, Wiley Online Library, MDPI, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Natsuo

Contact Natsuo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial

|
By Nagoya City, Yoshiyuki Nagumo, Tomokazu Kimura, Hitoshi Ishikawa, Yuta Sekino, Kazushi Maruo, Bryan Mathis, Jun Kamei, Hideomi Yamashita, Taku Naiki, Natsuo Tomita, Yasuyuki Kobayashi, Kotaro Yoshio, Yukio Kageyama, Hiroki Ushijima, Haruto Azuma, Keiji Nihei
| European Urology Verified
Keywords Bladder cancer Bladder preservation Atezolizumab Radiation therapy Clinical trial What does this study add? This study provides long-term outcomes of bladder preservation therapy involving a combination of atezolizumab and radiation therapy in patients with invasive bladder cancer who were unfit for or refused radical cystectomy.
Open in Who Shared Issue with article?

Impact of Craniocaudal Tumor Dimension and the Ninth Edition of the TNM Stage Classification on Prognosis in Resected Thymoma

|
By Natsuo Tomita, Katsuhiro Okuda, Eiji Nakatani, Dai Okazaki
| Wiley Online Library Verified
1 Introduction Thymomas represent the most common neoplasms of the anterior mediastinum, yet they are rare overall, with an incidence of approximately 0.13–0.32 per 100 000 individuals [1]. Previous studies reported that thymomas had a 10-year overall survival (OS) rate of 70%–90% [2-4], positioning them among malignancies with a favorable prognosis.
Open in Who Shared Issue with article?

Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis - Scientific Reports

|
By Natsuo Tomita
| Nature Verified
Abstract We compared survival outcomes of high-dose concomitant boost radiotherapy (HDCBRT) and conventional dose radiotherapy (CRT) for newly diagnosed glioblastoma (GB). Patients treated with intensity-modulated radiation therapy for newly diagnosed GB were included. In HDCBRT, specific targets received 69, 60, and 51 Gy in 30 fractions, while 60 Gy in 30 fractions was administered with a standard radiotherapy method in CRT.
Open in Who Shared Issue with article?
See all 7 articles